Literature DB >> 17592518

Functional interactions between presynaptic NMDA receptors and metabotropic glutamate receptors co-expressed on rat and human noradrenergic terminals.

E Luccini1, V Musante, E Neri, M Brambilla Bas, P Severi, M Raiteri, A Pittaluga.   

Abstract

BACKGROUND AND
PURPOSE: Electrophysiological studies described potentiation of NMDA receptor function by metabotropic glutamate receptors (mGluRs) of group I occurring postsynaptically. Since release-enhancing NMDA receptors exist on noradrenergic terminals and group I mGluRs have recently been identified on these nerve endings, we have investigated if NMDA receptor-mGluR interactions also can occur at the presynaptic level. EXPERIMENTAL APPROACH: Rat hippocampus and human neocortex synaptosomes were labelled with [(3)H]noradrenaline and superfused with mGluR agonists and antagonists. NMDA-evoked [(3)H]noradrenaline release was produced by removal of external Mg(2+) or by simultaneous application of NMDA and AMPA in Mg(2+)-containing solutions. KEY
RESULTS: The mGluR1/5 agonist 3,5-DHPG, inactive on its own, potentiated both the release of [(3)H]noradrenaline elicited by AMPA/NMDA/glycine and that evoked by NMDA/glycine following Mg(2+) removal. The effect of 3,5-DHPG on the AMPA/NMDA/glycine-induced release was insensitive to the mGluR1 antagonist CPCCOEt, but it was abolished by the mGluR5 antagonist MPEP; moreover, it was potentiated by the mGluR5 positive allosteric modulator DFB. When NMDA receptors were activated by Mg(2+) removal, both mGluR5 and mGluR1 contributed to the evoked release, the mGluR-mediated release being blocked only by CPCCOEt and MPEP in combination. Experiments with human neocortex synaptosomes show NMDA receptor-mGluR interactions qualitatively similar to those observed in rodents. CONCLUSIONS AND IMPLICATIONS: Group I mGluRs, both of the mGluR1 and mGluR5 subtypes, co-localize with NMDA receptors on noradrenergic terminals of rat hippocampus and human neocortex. Depending on the mode of activation, NMDA receptors exert differential permissive roles on the activation of presynaptic mGluR1 and mGluR5.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592518      PMCID: PMC2042940          DOI: 10.1038/sj.bjp.0707280

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  45 in total

Review 1.  Synaptosomes still viable after 25 years of superfusion.

Authors:  L Raiteri; M Raiteri
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

2.  Metabotropic glutamate autoreceptors of the mGlu(5) subtype positively modulate neuronal glutamate release in the rat forebrain in vitro.

Authors:  L S Thomas; D E Jane; J R Harris; M J Croucher
Journal:  Neuropharmacology       Date:  2000-07-10       Impact factor: 5.250

3.  Potentiation of a metabotropic glutamatergic response following NMDA receptor activation in rat hippocampus.

Authors:  A Lüthi; B H Gähwiler; U Gerber
Journal:  Pflugers Arch       Date:  1994-05       Impact factor: 3.657

4.  Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release.

Authors:  M Marti; F Paganini; S Stocchi; C Bianchi; L Beani; M Morari
Journal:  Eur J Neurosci       Date:  2001-10       Impact factor: 3.386

5.  mGluR1-mediated potentiation of NMDA receptors involves a rise in intracellular calcium and activation of protein kinase C.

Authors:  V A Skeberdis; J Lan; T Opitz; X Zheng; M V Bennett; R S Zukin
Journal:  Neuropharmacology       Date:  2001-06       Impact factor: 5.250

Review 6.  Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs.

Authors:  V Bruno; G Battaglia; A Copani; M D'Onofrio; P Di Iorio; A De Blasi; D Melchiorri; P J Flor; F Nicoletti
Journal:  J Cereb Blood Flow Metab       Date:  2001-09       Impact factor: 6.200

7.  Trafficking of presynaptic AMPA receptors mediating neurotransmitter release: neuronal selectivity and relationships with sensitivity to cyclothiazide.

Authors:  Anna Pittaluga; Marco Feligioni; Fabio Longordo; Elisa Luccini; Maurizio Raiteri
Journal:  Neuropharmacology       Date:  2005-10-19       Impact factor: 5.250

8.  Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes.

Authors:  Pascal Benquet; Christine E Gee; Urs Gerber
Journal:  J Neurosci       Date:  2002-11-15       Impact factor: 6.167

9.  Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons.

Authors:  Valerie Heidinger; Pat Manzerra; Xue Qing Wang; Uta Strasser; Shan-Ping Yu; Dennis W Choi; M Margarita Behrens
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

10.  Role of synaptic metabotropic glutamate receptors in epileptiform discharges in hippocampal slices.

Authors:  Angela C Lee; Robert K S Wong; Shih-Chieh Chuang; Hee-Sup Shin; Riccardo Bianchi
Journal:  J Neurophysiol       Date:  2002-10       Impact factor: 2.714

View more
  23 in total

Review 1.  Metabotropic glutamate receptor ligands as potential therapeutics for addiction.

Authors:  M Foster Olive
Journal:  Curr Drug Abuse Rev       Date:  2009-01

2.  Kinetic and system bias as drivers of metabotropic glutamate receptor 5 allosteric modulator pharmacology.

Authors:  Kathy Sengmany; Shane D Hellyer; Sabine Albold; Taide Wang; P Jeffrey Conn; Lauren T May; Arthur Christopoulos; Katie Leach; Karen J Gregory
Journal:  Neuropharmacology       Date:  2019-02-11       Impact factor: 5.250

3.  Immuno-Pharmacological Characterization of Presynaptic GluN3A-Containing NMDA Autoreceptors: Relevance to Anti-NMDA Receptor Autoimmune Diseases.

Authors:  Guendalina Olivero; Matteo Vergassola; Francesca Cisani; Cesare Usai; Anna Pittaluga
Journal:  Mol Neurobiol       Date:  2019-02-07       Impact factor: 5.590

Review 4.  Metabotropic glutamate receptor 5 as a potential target for smoking cessation.

Authors:  Cristiano Chiamulera; Claudio Marcello Marzo; David J K Balfour
Journal:  Psychopharmacology (Berl)       Date:  2016-11-16       Impact factor: 4.530

5.  Albuminuria and glomerular damage in mice lacking the metabotropic glutamate receptor 1.

Authors:  Aldamaria Puliti; Pia Irene Anna Rossi; Gianluca Caridi; Alessandro Corbelli; Masami Ikehata; Silvia Armelloni; Min Li; Cristina Zennaro; Valerio Conti; Carlotta Maria Vaccari; Michela Cassanello; Maria Grazia Calevo; Laura Emionite; Roberto Ravazzolo; Maria Pia Rastaldi
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

6.  Norepinephrine ignites local hotspots of neuronal excitation: How arousal amplifies selectivity in perception and memory.

Authors:  Mara Mather; David Clewett; Michiko Sakaki; Carolyn W Harley
Journal:  Behav Brain Sci       Date:  2015-07-01       Impact factor: 12.579

Review 7.  Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists.

Authors:  John H Krystal; Sanjay J Mathew; D Cyril D'Souza; Amir Garakani; Handan Gunduz-Bruce; Dennis S Charney
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

8.  MicroRNA-19b associates with Ago2 in the amygdala following chronic stress and regulates the adrenergic receptor beta 1.

Authors:  Naama Volk; Evan D Paul; Sharon Haramati; Chen Eitan; Brandon K K Fields; Raaya Zwang; Shosh Gil; Christopher A Lowry; Alon Chen
Journal:  J Neurosci       Date:  2014-11-05       Impact factor: 6.167

9.  Presynaptic mGlu1 and mGlu5 autoreceptors facilitate glutamate exocytosis from mouse cortical nerve endings.

Authors:  Veronica Musante; Elisa Neri; Marco Feligioni; Aldamaria Puliti; Marco Pedrazzi; Valerio Conti; Cesare Usai; Alberto Diaspro; Roberto Ravazzolo; Jeremy M Henley; Giuseppe Battaglia; Anna Pittaluga
Journal:  Neuropharmacology       Date:  2008-07-03       Impact factor: 5.250

10.  CXCR4 and NMDA Receptors Are Functionally Coupled in Rat Hippocampal Noradrenergic and Glutamatergic Nerve Endings.

Authors:  Silvia Di Prisco; Guendalina Olivero; Elisa Merega; Tommaso Bonfiglio; Mario Marchi; Anna Pittaluga
Journal:  J Neuroimmune Pharmacol       Date:  2016-05-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.